Syndax Pharmaceuticals, Inc. (SNDX) Stock Price

SNDXStock

$19.54+19.73%52W

Market Cap$1.74B

P/E—

PEG Ratio—

Div yield—

Beta0.42

SNDX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-16.75%

Price vs S&P 500 (4W)0.02%

VGM Score56.68

Book Value / Share (Quarterly)$0.17

P/TBV (Annual)2.31x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-44.66%

Cash Flow / Share (Quarterly)$-2.48

Price vs S&P 500 (YTD)-19.82%

Gross Margin (TTM)95.78%

Net Profit Margin (TTM)-87.52%

EPS (TTM)$-2.52

10-Day Avg Trading Volume1.10M

EPS Excl Extra (TTM)$-2.52

Revenue Growth (5Y)158.26%

EPS (Annual)$-3.29

ROI (Annual)-69.86%

Gross Margin (Annual)95.96%

Net Profit Margin (5Y Avg)-2021.44%

Cash / Share (Quarterly)$6.22

Revenue Growth QoQ (YoY)91.76%

ROA (Last FY)-53.88%

Revenue Growth TTM (YoY)222.65%

EBITD / Share (TTM)$-2.21

ROE (5Y Avg)-123.17%

Operating Margin (TTM)-76.98%

Cash Flow / Share (Annual)$-3.70

P/B Ratio115.44x

P/B Ratio (Quarterly)128.29x

Net Income / Employee (Annual)$-957,800

EV / Revenue (TTM)7.91x

Net Interest Coverage (TTM)-24.82x

ROA (TTM)-39.11%

EV / EBITDA (TTM)1765.24x

EPS Incl Extra (Annual)$-3.29

Current Ratio (Annual)4.40x

Quick Ratio (Quarterly)6.32x

3-Month Avg Trading Volume1.76M

52-Week Price Return19.73%

Revenue / Employee (TTM)$846,500

Tangible BV / Share (Quarterly)$5.16

P/S Ratio (Annual)10.11x

Asset Turnover (Annual)0.33x

52-Week High$25.59

Operating Margin (5Y Avg)-2033.49%

EPS Excl Extra (Annual)$-3.29

Tangible BV CAGR (5Y)34.98%

26-Week Price Return-4.82%

Quick Ratio (Annual)4.04x

13-Week Price Return-1.06%

Total Debt / Equity (Annual)5.32x

Current Ratio (Quarterly)6.77x

Enterprise Value$1.99B

Revenue / Share Growth (5Y)122.73%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)-32.47%

Revenue / Employee (Annual)$578,400

Pretax Margin (Annual)-165.60%

Cash / Share (Annual)$4.73

3-Month Return Std Dev45.35%

Net Income / Employee (TTM)$-740,800

ROE (Last FY)-441.62%

Net Interest Coverage (Annual)-7.66x

EPS Basic Excl Extra (Annual)$-3.29

Receivables Turnover (TTM)7.82x

Total Debt / Equity (Quarterly)38.95x

EPS Incl Extra (TTM)$-2.52

ROI (TTM)-47.56%

P/S Ratio (TTM)6.91x

Pretax Margin (5Y Avg)-2021.44%

Revenue / Share (Annual)$1.99

Tangible BV / Share (Annual)$6.86

Price vs S&P 500 (52W)1.17%

Year-to-Date Return-7.00%

5-Day Price Return-0.15%

EPS Normalized (Annual)$-3.29

ROA (5Y Avg)-31.30%

Net Profit Margin (Annual)-165.60%

Month-to-Date Return2.57%

Cash Flow / Share (TTM)$-2.59

EBITD / Share (Annual)$-3.15

Operating Margin (Annual)-158.45%

LT Debt / Equity (Annual)5.32x

ROI (5Y Avg)-36.84%

LT Debt / Equity (Quarterly)38.95x

EPS Basic Excl Extra (TTM)$-2.52

P/TBV (Quarterly)3.01x

P/B Ratio (Annual)28.25x

Inventory Turnover (TTM)0.42x

Pretax Margin (TTM)-87.52%

Book Value / Share (Annual)$0.74

Price vs S&P 500 (13W)-3.02%

Beta0.42x

P/FCF (Annual)60.11x

Revenue / Share (TTM)$2.83

ROE (TTM)-372.94%

52-Week Low$12.99

vGradeD

gGradeA

mGradeC

vgmGradeC

SNDX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$0.44	-$0.55	-26.01%(-$0.11)
Q1 2026	Apr 30, 2026	-$0.59	-$0.48	+18.76%(+$0.11)
Q4 2025	Feb 26, 2026	-$0.58	-$0.78	-34.89%(-$0.20)
Q3 2025	Nov 3, 2025	-$0.71	-$0.70	+1.54%(+$0.01)
Q2 2025	Aug 4, 2025	-$1.01	-$0.83	+17.50%(+$0.18)

SNDX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.35

4.37

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
SNDXSyndax Pharmaceuticals, Inc.	D	A	C	$19.54
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cancer and immune-related diseases. Its pipeline includes revumenib, a selective menin-MLL inhibitor for acute leukemias; axatilimab, a CSF-1R antibody for chronic graft-versus-host disease and pulmonary fibrosis; and entinostat, an oral small molecule targeting cancer cells and immune cells. The company is based in the United States.